Sysmex (OTCMKTS:SSMXY) Shares Gap Down – Here’s What Happened

Sysmex Corporation ADR (OTCMKTS:SSMXY) gapped down before the market opened on Monday . The stock had previously closed at $8.72, but opened at $8.36. Sysmex shares last traded at $8.37, with a volume of 3,981 shares trading hands.

Wall Street Analyst Weigh In

Separately, Citigroup cut shares of Sysmex from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 16th. One research analyst has rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold”.

Sysmex Price Performance

The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.44 and a current ratio of 3.33. The firm has a market cap of $5.39 billion, a price-to-earnings ratio of 17.83 and a beta of 1.10. The company’s fifty day moving average is $8.82 and its two-hundred day moving average is $9.55.

Sysmex (OTCMKTS:SSMXY) last posted its earnings results on Thursday, February 12th. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.01. The business had revenue of $837.32 million for the quarter, compared to analyst estimates of $819.99 million. Sysmex had a net margin of 8.86% and a return on equity of 9.27%. Equities research analysts forecast that Sysmex Corporation ADR will post 0.44 EPS for the current year.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan?based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high?speed, high?volume testing for blood cell counts and differential analysis.